Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective

Yaariv Khaykin; Peter J. Mallow; John A. Rizzo; Atul Verma; Lauren Chun; Shelby Olesovsky; Matthew R. Reynolds

doi:10.36469/9837

Loading [Contrib]/a11y/accessibility-menu.js

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:3023/feed

ISSN 2327-2236

Cardiovascular Conditions

Vol. 3, Issue 1, 2015

October 26, 2016 EDT

Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective

Yaariv Khaykin, Peter J. Mallow, John A. Rizzo, Atul Verma, Lauren Chun, Shelby Olesovsky, Matthew R. Reynolds,

markov modelcost-utilitycanadaatrial fibrillationcost-effectiveness

ccby-4.0

• https://doi.org/10.36469/9837

JHEOR

Khaykin Y, Mallow PJ, Rizzo JA, et al. Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective. JHEOR. 2016;3(1):1-12. doi:10.36469/9837

View more stats